| 韩 颖,蓝常肇,马少杰,罗 岚,王 红.小儿肺热咳喘口服液联合三联吸入雾化治疗法对哮喘急性发作的影响[J].,2020,(6):1116-1119 |
| 小儿肺热咳喘口服液联合三联吸入雾化治疗法对哮喘急性发作的影响 |
| Effect of Xiaoer Feirekechuan Oral Solution Combined with Triple Inhalation Atomization on Acute Attack of Asthma |
| 投稿时间：2019-10-08 修订日期：2019-10-31 |
| DOI：10.13241/j.cnki.pmb.2020.06.026 |
| 中文关键词: 哮喘 布地奈德 沙丁胺醇 异丙托溴铵 小儿肺热咳喘口服液 疗效 |
| 英文关键词: Asthma Budesonide Salbutamol Ipratropium bromide Xiaoer Feirekechuan Oral Solution Efficacy |
| 基金项目:首都卫生发展科研专项项目（2016-1-4071） |
|
| 摘要点击次数: 630 |
| 全文下载次数: 290 |
| 中文摘要: |
| 摘要 目的：探讨小儿肺热咳喘口服液联合三联吸入雾化治疗方案对哮喘患儿的治疗效果以及对肺功能的影响作用。方法：将我院自2017年1月至2018年11月间收治的哮喘患儿210例作为研究对象，按照随机数字表法分为两组各105例，研究组患儿在布地奈德、沙丁胺醇、异丙托溴铵三联吸入雾化治疗的基础上给予小儿肺热咳喘口服液进行治疗，对照组患儿仅给予三联雾化吸入治疗，对比观察两组患儿的疗效和预后。结果：研究组临床治疗后总有效率为95.24%，明显高于对照组77.14%（P＜0.05）；治疗后研究组咳嗽消失时间、呼吸困难消失时间和急性发作随诊时间均明显短于对照组（P＜0.05），两组肺部喘鸣音消失时间比较差异无统计学意义（P＞0.05）；治疗前患儿第一秒用力呼气量（forced expiratory volume in one second，FEV1）、最大肺活量（forced vital capacity，FVC）及FEV1/FVC值、呼气峰流速值（peak expiratory flowrate，PEF）对比无统计学意义（P>0.05），治疗后1 d、 3 d、7 d以上指标水平均明显升高，且在治疗后7 d，研究组明显高于对照组（P＜0.05）。治疗期间研究组有1例出现轻度腹泻，3例食欲减退，并发症的发生率为3.81%（4/105），对照组治疗期间2例出现轻度腹泻，4例食欲减退，并发症的发生率为5.71%（6/105），两组比较无统计学意义（P>0.05）。结论：使用小儿肺热咳喘口服液联合三联吸入雾化法治疗儿童哮喘急性发作，可改善患儿临床症状和肺功能，疗效显著，可推广使用。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the therapeutic effect of Xiaoer Feirekechuan Oral Solution combined with triple inhalation nebulization on children with asthma and lung function. Methods: Twenty-one patients with asthma admitted to our hospital from January 2017 to November 2018 were enrolled in the study. According to the random number table method, 105 patients in each group were included in the study group, budesonide, on the basis of salbutamol and ipratropium bromide triple inhalation and atomization treatment, Xiaoer Feirekechuan Oral Solution was given for treatment. The control group received only triple inhalation therapy, and the two groups of children were compared. The efficacy and prognosis. Results: The total effective rate of the study group was 95.24%, which was significantly higher than that of the control group(77.14%). The difference between the two groups was statistically significant (P<0.05). After treatment, the disappearance time of cough, the time of disappearance of dyspnea and the time of follow-up of acute attack were significantly shorter in the study group than in the control group (P<0.05). There was no significant difference in the disappearance time of pulmonary wheezing between the two groups (P>0.05). FEV1, FVC, FEV1/FVC, and PEF was no statistical significance (P>0.05). The levels of indicators above 1 d, 3 d, and 7 d after treatment were significantly higher, and the study group was significantly higher than the control group at 7 d after treatment (P<0.05). During the treatment period, 1 patient developed mild diarrhea, 3 patients had loss of appetite, and the incidence of complications was 3.81% (4/105). In the control group, 2 patients developed mild diarrhea, 4 patients had loss of appetite, and complications occurred. The incidence rate was 5.71%(6/105), and there was no significant difference between the two groups (P>0.05). Conclusion: The use of Xiaoer feirekechuan oral Solution combined with triple inhalation nebulization in the treatment of acute asthma attacks in children can improve the clinical symptoms and lung function of children, with remarkable curative effect and can be promoted. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
